Biologic

SAN DIEGO — Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, as well as with discontinuations, according to a series of posters presented here.

SAN DIEGO — Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here.

SAN DIEGO — Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically significant exacerbations, according to a poster abstract presented here.

SAN DIEGO — Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a median of zero after the first month and at 12 months, according to a poster presented here.

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host of related toxicities and adverse effects — has long been a goal for rheumatologists.

WASHINGTON — Patients with juvenile idiopathic arthritis receive biologic disease-modifying antirheumatic drugs significantly sooner on public insurance vs. private, particularly if they have oligoarticular JIA, according to a speaker.

PHILADELPHIA — The current biologics for patients with COPD include anti-IL-5 therapies, dupilumab, tezepelumab and anti-IL-33 therapies, according to a presentation at the 2024 GOLD COPD International Conference.

INDIANAPOLIS — Verséa Ophthalmics recently has introduced several new technologies for eye care, including the Biovance 3L Ocular amniotic membrane allograft and the T-POC quantitative testing platform for ocular surface disease.

WASHINGTON — In this video, Namrata Singh, MD, MSCI, spotlights three important abstracts in rheumatoid arthritis presented at ACR Convergence 2024.

In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.